跳至主要内容
临床试验/NCT00143221
NCT00143221已完成4 期

A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点目标入组 350 人开始时间: 2004年3月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
350
主要终点
Comparison of change in EF domain of IIEF at Week 12 between Viagra and placebo

研究概览

简要总结

The purpose of this study is to determine whether Viagra is effective in treating erectile dysfunction and lower urinary tract symptoms in men affected by both conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • clinical diagnosis of erectile dysfunction (ED)
  • lower urinary tract symptoms (LUTS)

排除标准

  • previous prostate surgery or invasive intervention for BPH
  • active urinary tract disease

结局指标

主要结局

Comparison of change in EF domain of IIEF at Week 12 between Viagra and placebo

次要结局

  • Effect on: IPSS Effect on IPSS QoL Orgasmic Function
  • Sexual Desire Intercourse Satisfaction and Overall Satisfaction domains of IIEF Qmax by uroflometry
  • Event Log Variables

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

相似试验